Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2014. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the company's issued share capital as of February 28, 2014:
- Total Issued Shares: 5,347,692,249 Ordinary Shares of 25p each.
- Treasury Shares: 488,929,169 Ordinary Shares.
- Total Voting Rights: 4,858,763,080.
No other material changes to operations or financial position are disclosed in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital.
Investor Verification Checklist
- Verify the total number of voting rights (4,858,763,080) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (488,929,169) as of February 28, 2014.
- Review the company's Form 20-F for comprehensive financial performance data not included in this 6-K.